Ameritas Investment Partners’s Lipocine LPCN Stock Holding History

Ameritas Investment Partners’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-76	Closed	-$5K	–	3023
2017 Q1	$5K	Buy	+76	New	+$4.93K	﹤0.01%	2839

Other funds holding LPCN

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DAM

DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Ameritas Investment Partners's LPCN Position: Q2 2017 in Review

Ameritas Investment Partners sold out of Lipocine (LPCN) in Q2 2017, closing a stake of 76 shares — an estimated $5K sold.

Ameritas Investment Partners first reported a position in LPCN in Q1 2017 and held it in 1 quarter. The position peaked at $5K in Q1 2017. 42 funds tracked by Wall St. Rank hold LPCN as of Q2 2017.

Ameritas Investment Partners reported no remaining Lipocine position as of Q2 2017 after selling out during the quarter.
Ameritas Investment Partners sold 76 Lipocine shares in Q2 2017, an estimated $5K.
Ameritas Investment Partners first reported a position in Lipocine in Q1 2017 and held it in 1 quarter.
Ameritas Investment Partners's Lipocine position peaked at $5K in Q1 2017.
42 funds tracked by Wall St. Rank held Lipocine as of Q2 2017.

Based on Ameritas Investment Partners's 13F filing for Q2 2017, filed 15 Aug 2017.